Chengcheng Zhu1, Xinrui Wang2,3, Laura Eisenmenger4, Zhang Shi2, Andrew Degnan5, Bing Tian2, Qi Liu2, Christopher Hess1, David Saloner1, Jianping Lu6. 1. Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA, USA. 2. Department of Radiology, Changhai Hospital, Shanghai, China. 3. Department of Radiology, General Hospital of Northern Theatre Command, Shenyang, China. 4. Department of Radiology, University of Wisconsin, Madison, WI, USA. 5. Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 6. Department of Radiology, Changhai Hospital, Shanghai, China. cjr.lujianping@vip.163.com.
Abstract
OBJECTIVE: This study aims to investigate whether aneurysm wall enhancement (AWE) is independently associated with symptomatic status of unruptured intracranial aneurysms (UIAs). METHODS: One hundred thirty-nine consecutive patients (67 male, mean age 58 ± 11 years) with 79 symptomatic and 87 asymptomatic UIAs were imaged using black-blood MRI pre- and post-gadolinium contrast administration and 3D DSA. Symptoms related to aneurysms were identified including cranial nerve deficits and headache. AWE grade and area were characterized, and aneurysm size was measured on DSA. Multivariate binary logistic regression analysis was used to identify factors associated with symptoms. Further subgroup analysis was performed for aneurysms size < 10 mm. RESULTS: Symptomatic UIAs had significantly larger aneurysm size (11.2 ± 6.2 mm vs. 6.4 ± 3.3 mm), enhancement grade (1.3 ± 0.6 vs. 0.4 ± 0.6), enhancement area (2.0 ± 0.9 vs. 0.4 ± 0.7), and higher prevalence of thick enhancement (39% vs. 3%) compared with asymptomatic UIAs, all p < 0.001. In multivariate analysis, only AWE area (odds ratio [OR] 6.9, 95% confidence interval [4.0, 11.7]) was independently associated with symptoms. AWE area had an area under curve (AUC) value of 0.888, with 72.2% sensitivity and 92.0% specificity for symptoms, which was superior to aneurysm size (AUC of 0.771, with 75.9% sensitivity and 65.5% specificity). In the subgroup analysis of aneurysms smaller than 10 mm (n = 118), AWE area (OR, 7.0, p < 0.001) remained the only independent risk factor associated with symptoms. CONCLUSIONS: Larger AWE area is independently associated with symptomatic UIAs, which may provide additional value to guide UIA management and improve patient outcomes. KEY POINTS: • Symptomatic intracranial aneurysms are larger and more often demonstrate significant wall enhancement than asymptomatic aneurysms. • Larger wall enhancement area is independently associated with symptomatic intracranial aneurysm.
OBJECTIVE: This study aims to investigate whether aneurysm wall enhancement (AWE) is independently associated with symptomatic status of unruptured intracranial aneurysms (UIAs). METHODS: One hundred thirty-nine consecutive patients (67 male, mean age 58 ± 11 years) with 79 symptomatic and 87 asymptomatic UIAs were imaged using black-blood MRI pre- and post-gadolinium contrast administration and 3D DSA. Symptoms related to aneurysms were identified including cranial nerve deficits and headache. AWE grade and area were characterized, and aneurysm size was measured on DSA. Multivariate binary logistic regression analysis was used to identify factors associated with symptoms. Further subgroup analysis was performed for aneurysms size < 10 mm. RESULTS: Symptomatic UIAs had significantly larger aneurysm size (11.2 ± 6.2 mm vs. 6.4 ± 3.3 mm), enhancement grade (1.3 ± 0.6 vs. 0.4 ± 0.6), enhancement area (2.0 ± 0.9 vs. 0.4 ± 0.7), and higher prevalence of thick enhancement (39% vs. 3%) compared with asymptomatic UIAs, all p < 0.001. In multivariate analysis, only AWE area (odds ratio [OR] 6.9, 95% confidence interval [4.0, 11.7]) was independently associated with symptoms. AWE area had an area under curve (AUC) value of 0.888, with 72.2% sensitivity and 92.0% specificity for symptoms, which was superior to aneurysm size (AUC of 0.771, with 75.9% sensitivity and 65.5% specificity). In the subgroup analysis of aneurysms smaller than 10 mm (n = 118), AWE area (OR, 7.0, p < 0.001) remained the only independent risk factor associated with symptoms. CONCLUSIONS: Larger AWE area is independently associated with symptomatic UIAs, which may provide additional value to guide UIA management and improve patient outcomes. KEY POINTS: • Symptomatic intracranial aneurysms are larger and more often demonstrate significant wall enhancement than asymptomatic aneurysms. • Larger wall enhancement area is independently associated with symptomatic intracranial aneurysm.
Entities:
Keywords:
Gadolinium; Intracranial aneurysm; Magnetic resonance imaging
Authors: Bing Tian; Shahed Toossi; Laura Eisenmenger; Farshid Faraji; Megan K Ballweber; S Andrew Josephson; Henrik Haraldsson; Chengcheng Zhu; Sinyeob Ahn; Gerhard Laub; Christopher Hess; David Saloner Journal: J Magn Reson Imaging Date: 2018-11-03 Impact factor: 4.813
Authors: E Kalsoum; A Chabernaud Negrier; T Tuilier; A Benaïssa; R Blanc; S Gallas; J-P Lefaucheur; A Gaston; R Lopes; P Brugières; J Hodel Journal: AJNR Am J Neuroradiol Date: 2018-03-29 Impact factor: 3.825
Authors: N Larsen; C von der Brelie; D Trick; C H Riedel; T Lindner; J Madjidyar; O Jansen; M Synowitz; C Flüh Journal: AJNR Am J Neuroradiol Date: 2018-07-19 Impact factor: 3.825
Authors: Anthony Portanova; Niloofar Hakakian; David J Mikulis; Renu Virmani; Wael M A Abdalla; Bruce A Wasserman Journal: Radiology Date: 2013-06 Impact factor: 11.105
Authors: Ashrita Raghuram; Alberto Varon; Sebastian Sanchez; Daizo Ishii; Chaorong Wu; Vincent A Magnotta; David M Hasan; Timothy R Koscik; Edgar A Samaniego Journal: Stroke Vasc Interv Neurol Date: 2022-05-08
Authors: Rob Molenberg; Marlien W Aalbers; Auke P A Appelman; Maarten Uyttenboogaart; J Marc C van Dijk Journal: Eur J Neurol Date: 2021-08-25 Impact factor: 6.288
Authors: Adam E Galloy; Ashrita Raghuram; Marco A Nino; Alberto Varon Miller; Ryan Sabotin; Carlos Osorno-Cruz; Edgar A Samaniego; Suresh M L Raghavan; David Hasan Journal: Front Neurol Date: 2021-12-10 Impact factor: 4.003